Five things for pharma marketers to know for Monday, October 20, 2025
The stock prices for Novo Nordisk and Eli Lilly dipped after President Donald Trump vowed to lower the price of weight loss drugs. Trump said that he would lower the price of Ozempic for Americans. (The Wall Street Journal)
Rani Therapeutics signed a deal worth up to $1.09 billion with Japan’s Chugai Pharma. Stocks of the biotherapeutics company surged 200%. (Seeking Alpha)
Novo hired industry veteran Greg Miley to head corporate affairs. This is amidst the company facing pricing pressures to lower the cost of weight loss drugs. (Bloomberg)
The Food and Drug Administration announced the first nine recipients of priority drug review vouchers. The review vouchers, called the Commissioner’s National Priority Review vouchers, is a program offering an expedited drug review to companies with products that align with the agency’s national health priorities. (STAT News)
An op-ed argued that the ongoing federal government shutdown is holding healthcare hostage. For 2026, marketplace filings show the largest proposed hikes since that shock — by a median 18 percent, with carriers citing hospital prices, utilization, pricey GLP-1s and the risk that enhanced Affordable Care Act tax credits expire. (The Hill)
To read last Friday’s edition of Five things for pharma marketers to know, click here.
